No Data
No Data
Hong Kong Stocks Alert | Microport (00853) fell more than 4%. Daiwa Securities' conservative assumption on its profit margin for the next few years led to a 14% decrease in target price.
Microport (00853) fell more than 4%, as of press time, down 4.41%, at HK$4.77, with a turnover of HK$9.824 million.
MicroPort NeuroTech Incentivizes Employees With Stock Options
Hong Kong stocks fluctuated | Medical device stocks rose in early trading, with micro-invasive stocks leading the gains. The National Medical Products Administration said it would spare no effort in promoting the research and development innovation of med
Medical instruments stocks collectively rose. As of the time of publication, Siasun Robot&Automation-B (02252) rose by 11.46% to 7.22 Hong Kong dollars; Microport (00853) rose by 8.48% to 4.99 Hong Kong dollars; AK Medical (01789) rose by 5.73% to 4.06 Hong Kong dollars; Microport Neuro-Science (02172) rose by 2.38% to 7.75 Hong Kong dollars; Weigao Group (01066) rose by 2.09% to 4.4 Hong Kong dollars.
Hong Kong stocks fluctuate | Orthopedic consumables concept stocks fall back, while orthopedics and others are still digesting the risk of price reductions in centralized procurement. The performance and valuation of leading enterprises are expected to gr
Orthopedic consumables concept stocks collectively fell back. As of the time of publication, Chunli Medical (01858) fell 5.35%, to HKD 6.72; AK Medical (01789) fell 4.7%, to HKD 3.65; Microport (00853) fell 2.34%, to HKD 4.59.
National Medical Insurance Bureau: The medical insurance department will vigorously promote the expansion and improvement of pharmaceutical central procurement.
Yan Qinghui, Deputy Director of the National Healthcare Security Administration, stated at the themed news conference that the next step for the medical insurance department will be to vigorously promote the expansion and improvement of the procurement of pharmaceuticals. They will continue to expand the coverage of centralized procurement and carry out centralized procurement of new batches of national organized medicines and high-value medical consumables, including artificial cochlea and other high-value medical consumables. At the same time, they will strengthen regional cooperation and guide local areas to promote the centralized procurement of chinese patent medicine, traditional chinese medicine decoction pieces, and in-vitro diagnostic reagents. They will steadily promote follow-up procurement and strengthen the refined management of centralized procurement. Together with relevant departments, they will enhance the management measures for the use, supply, and monitoring of selected products and urge t
Mainland China speeds up the implementation of centralized procurement of new batches of high-value medical consumables based on volume
Shi Zihai, Deputy Director of the National Medical Insurance Administration, recently led a team to Tianjin to investigate the centralized procurement of high-value medical consumables by national institutions. He stated that efforts should be made to accelerate the progress of the new batch of centralized volume-based procurement of high-value medical consumables by national institutions, and to include high-value medical consumables such as cochlear implants in the procurement scope. The market for consumables and clinical characteristics should be fully considered, and a "one product, one strategy" approach should be studied to improve the procurement rules. At the same time, we should focus on the implementation of the fourth batch of consumable procurement and the follow-up procurement of selected results for artificial joints after the expiration of the agreement, to ensure that the selected products are admitted to hospitals in a timely manner, guide and urge medical institutions to give priority to th
No Data
No Data